Skip to content Skip to menu
Australian Government Coat of Arms

Budget | 2015-16

Budget 2015-16
Australian Government Coat of Arms, Budget 2015-16

Part 2: Expense Measures (continued)

Health

Accelerating Growth in Organ and Tissue Donation for Transplantation

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Australian Organ and Tissue Donation and Transplantation Authority 5.9 2.2
Department of Human Services 1.3 ‑0.4
Department of Health 0.6 0.7
Total — Expense 7.8 2.4

The Government will provide $10.2 million over two years from 2015‑16 to improve organ and tissue donation and transplantation rates. Funding will deliver clinical education to hospitals, develop a new Australian Organ Matching System and enhance the Australian Organ Donor Register to enable the online registration of legal consent. In addition, the Supporting Leave for Living Organ Donors Programme will be continued to provide up to the minimum wage for up to nine weeks to employers of people who have taken leave to donate organs.

Better Targeted Rural Financial Incentives for Doctors

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Human Services 0.6 2.6 .. ‑0.1 ‑0.1
Department of Health ‑0.6 ‑2.6 .. 0.1 0.1
Total — Expense

The Government will reprioritise existing medical training programmes to better target assistance to rural areas with the highest level of health workforce need. Funding from the More Doctors for Outer Metropolitan Areas Relocation Incentive Grant and the Higher Education Contribution Scheme (HECS) Reimbursement Scheme will be redirected to the General Practice Rural Incentives Programme (GPRIP). The expanded GPRIP will be redesigned with a refined geographical classification system to increase the incentives for General Practitioners in smaller rural communities.

Bone Marrow Transplant and International Searches Programmes — consolidation

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health

The Government will consolidate the Bone Marrow Transplant and the International Searches Programmes into a new streamlined Haematopoietic Progenitor Cells Programme.

Consolidating these programmes will streamline the application and funding process and provide a single set of eligibility criteria, which will reduce the administrative burden for patients, hospital staff and the Australian Bone Marrow Donor Registry.

The cost of this measure will be met from within the existing resources of the Department of Health.

Ceasing the Alternative Arrangement Transfer to Pharmaceutical Benefits Programme — removal of anomaly

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health .. .. .. ..
Department of Human Services .. .. .. ..
Total — Expense .. .. .. ..

The Government will cease the Alternative Arrangement Transfer to Pharmaceutical Benefits Programme which funds Cohealth Ltd (Cohealth) to provide Pharmaceutical Benefits Scheme (PBS) medicines and pharmacy services to their clients in inner Melbourne.

Cohealth's clients pay an annual prescription fee to fill prescriptions rather than pay a PBS co‑payment each time they fill a prescription. The amount paid is equivalent to the PBS Safety Net. This measure reverses this anomaly as Cohealth's clients will now pay on a per prescription basis.

Child Dental Benefits Schedule — consistent indexation

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health ‑14.9 ‑25.3 ‑37.6 ‑47.7

The Government will achieve savings of $125.6 million over four years from 2015‑16 by broadly aligning indexation arrangements for both the benefits payable and the benefits cap under the Child Dental Benefits Schedule with indexation arrangements for other health benefits programmes.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Developing Northern Australia — positioning the north as a leader in tropical health

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Australian Trade Commission 1.4 2.2 2.7 2.3
National Health and Medical Research Council 0.9 2.2 2.2 1.5
Total — Expense 2.3 4.4 4.9 3.8

The Government will provide $15.3 million over four years to invest in research into exotic disease threats to Australia and the region.

$6.8 million over four years will be provided to the National Health and Medical Research Council to support research into tropical diseases, build collaboration and capacity in the health and medical research workforce, and promote the translation of this research into health policy and practice.

The Government will also provide $8.5 million over four years to establish an Australian Tropical Medicine Commercialisation grants programme to support Australian medical researchers to commercialise therapeutics and diagnostics in tropical medicine and to attract foreign investment.

This measure will form part of the Government's White Paper on Developing Northern Australia.

Improving Immunisation Coverage Rates

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 8.4 4.6 4.1 3.7
Department of the Treasury 1.8 1.9 1.9
Total — Expense 8.4 6.4 6.0 5.6

The Government will provide $26.4 million over four years for a range of activities designed to improve immunisation coverage and further reduce the incidence of vaccine preventable diseases in the Australian community.

Immunisation coverage rates will be increased by broadening immunisation data collection to record all school‑based adolescent vaccinations; introducing better targeted performance benchmarks for states and territories; providing incentives to health providers, including to General Practitioners, to provide catch up vaccinations to children who are overdue for immunisation; and providing a community awareness campaign to increase awareness of the National Immunisation Programme and dispel myths about immunisation.

Further information can be found in the press release of 19 April 2015 issued by the Minister for Health.

See also the related expense measure titled No Jab No Pay in the Social Services Portfolio.

Junior Medical Officer Programme — interagency transfer from the Department of Veterans' Affairs

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 10.0 10.0 10.0 10.0
Department of Veterans' Affairs ‑10.0 ‑10.0 ‑10.0 ‑10.0
Total — Expense

The Government will transfer responsibility for the Junior Medical Officer Programme from the Department of Veterans' Affairs to the Department of Health, to align responsibility for health workforce programmes within a single portfolio.

The Junior Medical Officer Programme provides training for junior doctors at the Greenslopes Private Hospital in Queensland and the Hollywood Private Hospital in Western Australia.

Medicare Benefits Schedule — changes to GP rebates — reversal

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 182.7 657.8 699.0 726.5 762.8
Department of Veterans' Affairs 3.5 6.4 6.0 5.7 5.4
Department of Human Services ‑4.7 ‑18.3 ‑13.4 ‑13.9 ‑14.2
Total — Expense 181.4 645.9 691.6 718.3 754.1
Department of Human Services ‑0.3 ‑0.2

The Government will not proceed with measures originally announced in the Mid‑Year Economic and Fiscal Outlook 2014‑15 to redefine the time requirements for Level A and B GP consultation items and to reduce rebates by $5 for common GP consultations and after hours services to non‑concessional patients aged 16 and over.

Further information can be found in the press releases of 15 January 2015 and 3 March 2015 issued by the Minister for Health.

Medicare Benefits Schedule — health assessment items — modification

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Human Services 0.1 ‑0.2 ‑0.2 ‑0.2
Department of Health ‑20.0 ‑36.2 ‑41.3 ‑46.7
Total — Expense ‑19.9 ‑36.3 ‑41.4 ‑46.9

The Government will achieve savings of $144.6 million over four years by removing the current duplication between health assessments under the Medicare Benefits Schedule and the child health assessments already provided by the states and territories.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Medicare Benefits Schedule — new and amended listings

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 8.4 11.3 9.9 8.4
Department of Veterans' Affairs 0.3 0.4 0.3 0.3
Department of Human Services .. 0.2 0.1 0.1 0.1
Total — Expense .. 8.8 11.8 10.3 8.8

The Government will amend the Medicare Benefits Schedule (MBS) and Veterans' Benefits for new and amended items listed since the Mid‑Year Economic and Fiscal Outlook 2014‑15, at a net cost of $39.8 million over four years.

The amendments to the MBS include:

  • introducing rebates for second expert opinions for diagnoses related to the testing of bone marrow specimens, tissue pathology and cytopathology;
  • new items for the treatment of early stage breast cancer using targeted intraoperative radiotherapy;
  • new items to enable routine monitoring of implanted cardiac devices to be provided remotely; and
  • extending eligibility for the use of telehealth services to optometrists, to support the use of video consultations with specialist ophthalmologists.

Further information will be available in the summary of changes included in the MBS issued by the Department of Health when the amendments take effect.

Medicare Benefits Schedule — review and reform

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 17.0 17.3

The Government will provide $34.3 million over two years from 2015‑16 to continue the Medical Services Advisory Committee's activities and deliver an expanded process of MBS Review overseen by a clinician led Medicare Benefits Schedule Review Taskforce.

The Government will continue to consult with stakeholders on primary care through the establishment of a Primary Health Care Advisory Group, which will include primary health care professionals, health economists and health academics.

Further information can be found in the press release of 22 April 2015 issued by the Minister for Health.

My Health Record — a new direction for electronic health records in Australia

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Finance ‑0.1 ‑0.1 ..
Department of Veterans' Affairs ‑0.1 ‑0.1
Department of Human Services ‑12.5 ‑15.9 ‑8.6 0.2
Department of Health ‑39.6 ‑82.2 ‑41.0 5.1
Total — Expense ‑52.2 ‑98.3 ‑49.6 5.3
Department of Human Services ‑0.7 ‑2.1 ‑0.4
Department of Health ‑9.5 ‑6.7
Total — Capital ‑10.1 ‑8.8 ‑0.4

The Government will provide $485.1 million over four years to continue the operation of the eHealth system, make key system and governance improvements and implement trials of opt‑out arrangements.

Personally Controlled Electronic Health Records (PCEHR) will be renamed as My Health Records and the Government will provide national coordination for eHealth by transitioning governance arrangements from the National E‑Health Transition Authority to the new Australian Commission for eHealth. Trials will be held in at least two regions in 2016 and will assess public and provider responses to revised participation arrangements, including to an opt‑out model.

The Department of Finance will undertake a Gateway review of the My Health Record system and will provide independent assurance to improve delivery and implementation.

Funding of $699.2 million for the redevelopment of the PCEHR was provisioned for in the contingency reserve at the 2014‑15 Budget.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

National Cervical Screening Programme — reform

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 2.2 2.0 ‑0.1 ‑0.6
Department of Human Services ‑0.3 ‑1.6 ‑1.6
Total — Expense 2.2 1.7 ‑1.7 ‑2.2

The Government will reform the National Cervical Screening Programme (NCSP), in line with recommendations from the Medical Services Advisory Committee, at a net cost of $13,000 over four years from 2015‑16.

From 1 May 2017, the current two‑yearly Pap test will be replaced by a five‑yearly primary Human Papilloma Virus test for women aged from 25 to 74 years. This reform will reduce the number of screening tests over a woman's lifetime and is expected to decrease the mortality and morbidity from cervical cancer by at least 15 per cent.

The Government is also committed to developing a National Cancer Screening Register to replace the current state and territory registers for the NCSP and the National Bowel Cancer Screening Register.

National Critical Care and Trauma Response Centre — continuation

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health
Department of the Treasury

The Government will provide $63.5 million over four years to enable the continued operation of the National Critical Care and Trauma Response Centre (NCCTRC) at the Royal Darwin Hospital. The NCCTRC enables the timely deployment of skilled medical personnel and supporting equipment in response to major incidents in Australia and South East Asia. Funds will be provided through a new National Partnership with the Northern Territory Government.

Funding for this measure has already been provided for by the Government.

National Drugs Campaign — renewal

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 10.0 10.0

The Government will provide $20.0 million over two years from 2015‑16 to renew the National Drugs Campaign, which is a national media campaign to promote the avoidance and cessation of illicit drug use. In 2015‑16 and 2016‑17 the campaign will focus on young people and their parents and seek to raise awareness of the harm caused by illicit drug use, in particular the form of methamphetamine known as 'ice'.

National Immunisation Programme — new and amended listings

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 0.1 6.2 42.8 43.8 37.9
Department of Human Services 2.3 8.2 5.9 5.4
Department of the Treasury 0.1 0.7 1.6 1.6
Total — Expense 0.1 8.5 51.6 51.3 44.8
Department of Human Services 2.4 2.8 0.4

The Government will provide $161.8 million over five years from 2014‑15 for new and amended listings under the National Immunisation Programme (NIP), which include:

  • Diptheria, Tetanus and Acellular Pertussis (DTPa) vaccine for the prevention of Diptheria, Tetanus and whooping cough for children aged 18 months from 1 January 2016; and
  • Zostavax vaccine for the prevention of shingles for 70 year olds, including a five year programme to provide 71‑79 year olds with an opportunity for a catch‑up vaccination, from 1 November 2016.

An adult vaccination register will be established to record all adult vaccines provided under the NIP from 1 September 2016. Establishing the adult register will assist with the monitoring of safety, quality and delivery of vaccinations to the adult population.

National Joint Replacement Levy — amendments

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 0.1 0.1 0.2 0.2
Department of Health 0.1 0.1 0.2 0.2

The Government will change the method for calculating the National Joint Replacement Registry (NJRR) levy so that it is proportionate to a company's market share from 1 July 2015. The total levy will increase by $0.6 million over the four years from 2015‑16 to support the increased activity of the NJRR.

The NJRR collects demographic data related to joint replacement surgery in Australia and monitors the performance of all joint replacement prostheses used in Australia to support improved quality of care for patients.

National Partnership Agreement on Adult Public Dental Services — one year funding

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health
Department of the Treasury

The Government will provide $155.0 million in 2015‑16 for a one year agreement to replace the existing National Partnership Agreement on Adult Public Dental Services. The agreement will support the provision of dental health services to adults who rely on the public dental system.

Funding for this measure has already been provided for by the Government.

Pharmaceutical Benefits Scheme — increase in the safety net thresholds on 1 January 2019

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Veterans' Affairs ‑0.1
Department of Health ‑5.0
Total — Expense ‑5.1

The Government will achieve savings of $5.1 million in 2018‑19 by extending the increases to the Pharmaceutical Benefits Scheme (PBS) safety net thresholds by one additional year in 2019.

This measure builds on the 2014‑15 Budget measure titled Pharmaceutical Benefits Scheme — increase in co‑payments and safety net thresholds which increased the PBS safety net thresholds each year for four years from 1 January 2015, with general safety net thresholds to increase by 10 per cent each year and concessional safety nets to increase by the cost of two prescriptions each year.

The Government has revised the start date of this measure to 1 January 2016, with the final increases in the safety net thresholds to now occur on 1 January 2019.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Pharmaceutical Benefits Scheme — new and amended listings

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 5.9 375.4 381.6 391.2 377.7
Department of Veterans' Affairs .. 7.5 8.2 8.1 7.9
Department of Human Services 0.7 5.3 1.7 1.8 1.9
Total — Expense 6.7 388.2 391.4 401.1 387.5
Department of Health nfp nfp nfp nfp nfp

The Government will provide $1.6 billion over five years for a number of new and amended listings on the Pharmaceutical Benefits Scheme and the Repatriation Pharmaceutical Benefits Scheme.

New and amended listings since the Mid‑Year Economic and Fiscal Outlook 2014‑15 include:

  • Myozyme® (Alglucosidase alfa‑rch) for the treatment of Pompe disease from 1 February 2015;
  • Lemtrada® (Alemtuzumab) for the treatment of relapsing‑remitting multiple sclerosis from 1 April 2015;
  • Lucrin® (Leuprorelin) for the treatment of Central Precocious Puberty from 1 April 2015;
  • Xolair® (Omalizumab) for the treatment of asthma from 1 May 2015;
  • Erbitux® (Cetuximab) for the treatment of metastatic colorectal cancer from 1 June 2015;
  • Kadcyla® (Transtuzumab Emtansine), Perjeta® (Pertuzumab) and Herceptin® (Trastuzumab) for the treatment of metastatic breast cancer from 1 July 2015; and
  • Mekinist® (Trametinib) for the treatment of melanoma from 1 August 2015.

The new listing of Herceptin® mainstreams its treatment, making the previous spending programme unnecessary.

Pharmaceutical Benefits Scheme — price changes

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of the Treasury 0.1 0.4 0.5 0.5 0.5
Department of Veterans' Affairs ‑0.5 ‑1.8 ‑1.6 ‑1.7 ‑1.8
Department of Health ‑13.3 ‑53.9 ‑54.4 ‑59.6 ‑65.5
Total — Expense ‑13.7 ‑55.2 ‑55.6 ‑60.8 ‑66.9

The Government will achieve savings of $252.2 million over five years for price amendments for certain medicines currently listed on the Pharmaceutical Benefits Scheme and the Repatriation Pharmaceutical Benefits Scheme.

Price amendments since the Mid‑Year Economic and Fiscal Outlook 2014‑15 include:

  • Etoposide for the treatment of cancer;
  • Ezetimibe with simvastatin for the treatment of dyslipidemia;
  • Fluticasone with salmeterol for the management of asthma and chronic obstructive pulmonary disease; and
  • Hexamine for the treatment of urinary tract infections.

These price amendments are the result of Pharmaceutical Benefits Advisory Committee recommendations.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Practice Incentives Programme After Hours Payment

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Human Services 1.5 0.2 0.2 0.3 0.3
Department of Health ‑1.8 ‑0.2 ‑0.3 ‑0.3
Total — Expense 1.5 ‑1.5 .. ..

The Government will refocus after hours primary care funding by introducing a new Practice Incentives Programme (PIP) After Hours Payment from 1 July 2015. The PIP After Hours Payment will encourage eligible general practices to provide after hours care for their patients.

The cost of this measure will be met by redirecting funding from the After Hours GP Helpline and the Medicare Locals After Hours Programme.

Rationalising and streamlining Health programmes

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Human Services ..
Department of Health ‑12.0 ‑121.5 ‑215.7 ‑276.3 ‑337.2
Total — Expense ‑12.0 ‑121.5 ‑215.7 ‑276.3 ‑337.2

The Government will achieve savings of $962.8 million over five years from 2014‑15 by rationalising and streamlining funding across a range of Health programmes, including:

  • the Health Portfolio Flexible Funds;
  • dental workforce programmes, including by redesigning incentives in the Dental Relocation and Infrastructure Support Scheme to encourage dentists to relocate to smaller rural centres;
  • preventative health research;
  • GP Super Clinics which have not yet commenced construction;
  • ceasing the Inborn Error of Metabolism programme, as key medicines are now listed on the Pharmaceutical Benefits Scheme and low protein foods are now much more readily available at lower cost; and
  • by piloting competitive tendering for a subset of products in the Stoma Appliance Scheme.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Reducing the Burden of the Industrial Chemicals Regulatory Framework to Industry

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 2.5 2.5 0.4
Department of Health 2.5 2.5 1.4 1.8
Department of Health 3.5 3.5

The Government will provide $4.2 million over four years from 2015‑16 to amend the Industrial Chemicals (Notification and Assessment) Act 1989 to focus regulatory assessment on industrial chemicals that pose the greatest risk and to develop streamlined assessment processes for new and existing chemicals, including using existing international approvals where appropriate. This will reduce the regulatory burden of the industrial chemicals regulatory framework and remove unnecessary barriers to the entry to market of lower risk chemicals, while maintaining the protection of public health and the environment.

The cost of this measure will be fully funded by industry through increased industrial chemical levies between 2015‑16 and 2021‑22.

Smaller Government — Health Portfolio

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health ‑3.2 ‑14.8 ‑29.3 ‑32.8 ‑33.0

The Government will achieve savings of $113.1 million over five years from 2014‑15 through:

  • creating operational efficiencies in the delivery of corporate services by amalgamating the corporate and legal services of the Therapeutic Goods Administration into the corporate functions of the Department;
  • ceasing activities in the Department that mirror the work of specialist agencies such as the Independent Hospital Pricing Authority; Australian Organ and Tissue Donation and Transplantation Authority; National Blood Authority; National Health Performance Authority; Australian Commission on Safety and Quality in Health Care; National Health and Medical Research Council; and the Australian Institute of Health and Welfare;
  • ceasing the National Lead Clinicians Group from 1 July 2015;
  • rationalising the structure of the Department to more effectively respond to the Government's health policy priorities;
  • rationalising business and financial management support functions across the Department;
  • reducing contractor costs by recruiting ongoing staff to replace IT contractors; and
  • reducing the Department's property footprint and consolidating staff into current locations.

The Government will reinvest $10.0 million over four years to further develop the in‑house data analytical, economics and research capacity of the Department, including engaging external expertise and developing data links with other Government agencies as necessary.

This measure is part of the fourth phase of the Smaller Government reforms which reduce the size and complexity of government.

The Smaller Government reforms are eliminating duplication and waste, streamlining services and reducing the cost of government administration.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Stoma Appliance Scheme — new and amended listings

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health ‑1.6 ‑1.8 ‑2.0 ‑2.2

The Government will achieve savings of $7.6 million over four years through the listing of two new items, amending the prices of 21 current items and deleting of one item on the Stoma Appliance Scheme from 1 July 2015 as recommended by the Stoma Product Assessment Panel.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Streamlining Health Workforce Scholarships

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health ‑14.2 ‑17.6 ‑19.0 ‑21.7

The Government will achieve $72.5 million in savings over four years by streamlining nine existing health workforce scholarships into a single Health Workforce Scholarship Programme that creates consistency in rules and obligations and provides greater flexibility to respond to health workforce priorities. A return of service obligation will apply and will require recipients to work in rural or regional areas for one year. Additionally, the existing 100 Commonwealth Supported Places per year under the Medical Rural Bonded Scholarship scheme will be transferred to the Bonded Medical Places scheme.

The number of scholarships aimed at increasing Aboriginal and Torres Strait Islander health workforce participation will not be reduced nor be subject to the return of service obligation.

The savings from this measure will be redirected by the Government to fund other Health policy priorities or will be reinvested into the Medical Research Future Fund.

Supporting the Royal Flying Doctor Service

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health 9.9 10.1

The Government will provide additional funding of $20.0 million over two years from 2015‑16 to support the Royal Flying Doctor Service to deliver emergency and primary health care services to people in rural and remote communities of Australia.

The measure supports the Government's commitment to rural and remote communities.

Tobacco Plain Packaging Litigation

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Health nfp nfp nfp nfp

The Government will provide funding to defend international legal challenges to the Tobacco Plain Packaging Act 2011, which is the subject of dispute settlement proceedings instituted by five countries in the World Trade Organisation.

The funding will support work undertaken by the Department of Health, the Attorney General's Department, the Department of Foreign Affairs and Trade and the Australian Government Solicitor to defend the litigation.

The expenditure for this measure is not for publication (nfp) to protect the Australian Government's position in any litigation.

Wimmera Health Care Group — Oncology, Dialysis and Community Palliative Care Centre

Expense ($m)
2014‑15 2015‑16 2016‑17 2017‑18 2018‑19
Department of Infrastructure and Regional Development
Department of Health 1.0
Total — Expense 1.0

The Government will provide $1.0 million in 2014‑15 to the Wimmera Health Care Group to support the redevelopment of the Oncology, Dialysis and Community Palliative Care Centre in Horsham, Victoria.

This contribution will supplement the $1.0 million of privately‑raised money that will go towards making this a much better cancer centre for the people of this region.

The cost of this measure will be met from within the existing resources of the Department of Infrastructure and Regional Development.

Further information can be found in the press release of 12 March 2015 issued by the Prime Minister.